Study Summary
This trial is testing a new drug for prostate cancer that has resisted other treatments. They are testing to see if it is safe and tolerable for humans.
- Metastatic Castration Resistant Prostate Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 4 Secondary · Reporting Duration: Approximately 6 months
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
LAVA-1207
1 of 1
Experimental Treatment
66 Total Participants · 1 Treatment Group
Primary Treatment: LAVA-1207 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the maximum number of patients that can be enrolled in this clinical trial?
"The sponsor, Lava Therapeutics, needs to recruit 66 patients that fit the study's inclusion criteria from their various locations. Two notable sites are Washington University School of Medicine in St. Louis, Missouri and Huntsman Cancer Institute, University of Utah located in Salt Lake City." - Anonymous Online Contributor
Are people still able to sign up for this research program?
"That is correct. The information available on clinicaltrials.gov reveals that this research project, which was originally published on June 27th 2022, is still recruiting patients. In total, 66 individuals are needed for the study to be conducted at 4 different hospitals or clinics." - Anonymous Online Contributor
What is the purpose of this clinical trial?
"The primary objective of this clinical trial, as measured over a period of approximately 6 months, is to assess the frequency and type of DLT (defined as Development of antibodies (anti-drug antibodies) to LAVA-1207). In addition to the primary outcome, this study will also evaluate secondary outcomes including the incidence and prevalence of anti-LAVA-1207 antibodies (defined as Binding of LAVA-1207 to Vγ9Vδ2-T cells), biomarkers, binding of LAVA-1207 to Vγ9Vδ2-T cells (defined as measuring the binding of" - Anonymous Online Contributor
Is this clinical trial available in more than one Canadian province?
"The trial is being conducted at Washington University School of Medicine in St. Louis, Missouri; Huntsman Cancer Institute, University of Utah in Salt Lake City, Utah; Moffitt Cancer Center in Tampa, Florida and 4 other locations." - Anonymous Online Contributor